<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>PD-L1 on CMC Seoul OBY &amp; Breast Pathology</title>
    <link>https://extraordinary-tulumba-269604.netlify.app/categories/pd-l1/</link>
    <description>Recent content in PD-L1 on CMC Seoul OBY &amp; Breast Pathology</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 11 Jun 2022 00:00:00 +0000</lastBuildDate><atom:link href="https://extraordinary-tulumba-269604.netlify.app/categories/pd-l1/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>PD-L1 Interpretation Manual</title>
      <link>https://extraordinary-tulumba-269604.netlify.app/docs/breast/2022-06-11-pd-l1-ihc-22c3-pharmdx-interpretation-manual-triple-negative-breast-cancer-tnbc/</link>
      <pubDate>Sat, 11 Jun 2022 00:00:00 +0000</pubDate>
      
      <guid>https://extraordinary-tulumba-269604.netlify.app/docs/breast/2022-06-11-pd-l1-ihc-22c3-pharmdx-interpretation-manual-triple-negative-breast-cancer-tnbc/</guid>
      <description>VENTANA PD-L1 (SP142) Assay IC staininghttps://diagnostics.roche.com/content/dam/diagnostics/us/en/products/v/ventana-pd-l1-sp142-assay/VENTANA-PD-L1-SP142-Assay-TNBC-IG.pdf
PD-L1 IHC 22C3 pharmDx Interpretation Manual – Triple-Negative Breast Cancerhttps://www.agilent.com/cs/library/usermanuals/public/29389_22c3_pharmdx_tnbc_interpretation_manual_kn355.pdf
PD-L1 IHC 22C3 pharmDx Interpretation Manual – Cervical Cancerhttps://www.agilent.com/cs/library/usermanuals/public/29257_22c3_pharmDx_cervical_interpretation_manual_us.pdf</description>
    </item>
    
  </channel>
</rss>
